Member Exclusive INTERVIEW

Keeping patients safe from unproven cell therapies: an interview with the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies

In this interview, Bruce Levine, President-Elect of the International Society for Cell and Gene Therapy (ISCT) and member of the Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies, discusses the ISCT’s new patient resources.

Thumb rme journal large
Feb 05, 2019
2
2

Please sign in or register for FREE

2 Comments

Thumb default avatar
David T Harris 4 months ago

Not sure that any of these articles are doing much good out in the real world.  Stem cell clinics have now made their way to our community big time.  A company called Stem Cell Centers is running prime time TV ads and full page newspaper ad every week.  I attended several presentations by different companies and found it be outright misleading and inaccurate.  I complained to our local IRB who referred me to the FDA, FTC and state board of medicine.  No help whatsoever.  It may be a better tack to try and associate these clinics on the same level as pop-up used car lots.

Thumb rme journal large
RegMedNet 4 months ago

Thank you for your comment, David. We contacted Bruce for a response, who shared the following statement:

"We appreciate and share the concern expressed by Professor Harris. The ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapy strives to identify key aspects of unproven cellular interventions in order to promote and share effective strategies between scientific/medical societies, health-care stakeholders, patient associations, and individuals, to promote the role of rigorous research and appropriate investigation and application of cell based therapies.  While these “clinics” are pervasive, we believe education of the public and professionals alike is one component of a broader strategy that will help inform patients and families to possibly dissuade them from investing false hope and from unpredictable side effects.  Though we are encouraged by recent FDA actions, we hope that these, as well as actions by other appropriate oversight bodies, will accelerate to protect patients from physical and financial harm. "